Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 9/20 | 0.65 |
| ▸ | BCHE | P06276 | 2/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8908408 | 0.90 | CCR3 (0.63) | CCR3ACHEBCHEHRH3 | |
| SCHEMBL12513916 | 0.90 | CCR3 (0.58) | CCR3ACHEBCHEHRH3ALDH1A1 | |
| SCHEMBL4789907 | 0.89 | CCR3 (0.61) | CCR3ACHEBCHEHRH3 | |
| SCHEMBL15140944 | 0.87 | CCR3 (0.73) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL12044684 | 0.87 | KCNH2 (0.61) | CCR3ACHEBCHEHRH3 | |
| SCHEMBL12040802 | 0.87 | KCNH2 (0.61) | CCR3ACHEBCHEHRH3 | |
| SCHEMBL2735346 | 0.86 | CCR3 (0.71) | CCR3ACHEALDH1A1CXCR4 | |
| SCHEMBL3107807 | 0.86 | CCR3 (0.71) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL24404498 | 0.84 | CCR3 (0.69) | CCR3ACHEBCHEHRH3 | |
| SCHEMBL4499901 | 0.84 | CCR3 (0.69) | CCR3ACHEBCHEALDH1A1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111925357-A | Acylhydrazone compound, pharmaceutical composition and application thereof | 中国科学院昆明植物研究所 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019046784-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-9981972-B2 | N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| US-20170183353-A1 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR INDETIFICATION OF SERINE HYDROLASE TARGETS | H. LUNDBECK A/S (DK) | 2017-06-29 | — | — | US | disclosed |
| US-9546153-B2 | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-09-22 | — | — | US | disclosed |
| WO-2016123387-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-9328071-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2016-05-03 | — | — | US | disclosed |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-01 | — | — | US | disclosed |
| US-20100189773-A1 | 5-CYANO-4- (PYRROLO [2,3] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-29 | — | — | US | disclosed |
| US-20100168114-A1 | INVERTEBRATE ACETYLCHOLINESTERASE INHIBITORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2010-07-01 | — | — | US | disclosed |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080312091-A1 | INVERTEBRATE ACETYLCHOLINESTERASE INHIBITORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2008-12-18 | — | — | US | disclosed |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. | 2008-10-23 | — | — | US | disclosed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070105781-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
| US-5610303-A | MONOAMIDE OXIDASE INHIBITORS | UBE INDUSTRIES, LTD. (JP) | 1997-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168114-A1 | INVERTEBRATE ACETYLCHOLINESTERASE INHIBITORS | ACHE, BCHE, CHAT | CCR3 4292/4885ACHE 1/4885BCHE 2/4885 |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK1, IRAK3 | CCR3 1411/4885ACHE 4610/4885BCHE 4682/4885 |
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | CCR3 1019/4885ACHE 4772/4885BCHE 4680/4885 |
| US-20100189773-A1 | 5-CYANO-4- (PYRROLO [2,3] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K5, CDK5, MAP3K20 | CCR3 2340/4885ACHE 3014/4885BCHE 3085/4885 |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | CCR3 4084/4885ACHE 1975/4885BCHE 1658/4885 |
| US-20070105781-A1 | Inhibitors of serine proteases | PRSS1, SERPINB1, PRSS3 | CCR3 857/4885ACHE 1686/4885BCHE 419/4885 |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | MUSK, RNASE1, DPYD | CCR3 2884/4885ACHE 66/4885BCHE 2121/4885 |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | CCR3 1016/4885ACHE 3961/4885BCHE 4117/4885 |
| US-20170183353-A1 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR INDETIFICATION OF SERINE HYDROLASE TARGETS | HPN, BCHE, PRSS1 | CCR3 1854/4885ACHE 119/4885BCHE 2/4885 |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | CCR3 3758/4885ACHE 1502/4885BCHE 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.